GSK/XenoPort file sNDA for Horizant in PHN
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has filed a supplemental new drug application (sNDA) in the US requesting approval of XenoPort's Horizant (gabapentin enacarbil) extended-release tablets for the management of postherpetic neuralgia (PHN) in adults.